Clinical Trials Logo
  1. Home
  2. Metastatic Solid Tumors
  3. NCT03403725

MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study — CD205SHUTTLE  

Metastatic Solid Tumors Clinical Trial

Official title:
Open-Label, Multicenter, Phase I Dose Escalation Study of MEN1309, a CD205 Antibody-Drug Conjugate,in Patients With CD205-Positive Metastatic Solid Tumors and Non-Hodgkin Lymphoma

Clinical Trial Summary

The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with acceptable safety profile and that can be used in patients affected by CD205-positive solid tumors and Non-Hodgkin Lymphoma

Clinical Trial Description

This clinical trial will investigate the safety and activity of MEN1309 in patients with CD205-positive metastatic solid tumors and Non-Hodgkin Lymphoma who have tried other types of treatment for cancer without adequate response (or the cancer came back). CD205 is a protein present in certain types of cancer. This is a Phase I study, which means that it is designed to look at several dose levels of a study drug in small groups of patients to find the dose that is well-tolerated and suitable to be administered in subsequent clinical trials in patients. The clinical trial is also looking at the effectiveness of the study drug. This is the first time the study drug will be given in humans. The clinical trial consists of two sequential parts: - Part 1 involves patients with CD205-positive metastatic solid tumors and the main purpose of this part of the clinical trial is to determine the highest dose of the study drug that can be used safely in these type of cancers. - Part 2 involves patients with CD205-positive Non-Hodgkin Lymphoma and will test doses of MEN1309 which have demonstrated to be adequately tolerated in patients with solid tumors. Patients participating to the clinical trial will take the study drug as intravenous infusion once every 3 weeks. The clinical trial includes four periods: a pre-screening period (to check if tumor is positive for CD205), a screening period (to check whether the participation to the clinical trial is right for patient), a treatment period (when patient receives the study drug), and a follow-up period (to check the health status of the patient after stopping study treatment). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03403725
Study type Interventional
Source Menarini Group
Contact
Status Terminated
Phase Phase 1
Start date August 28, 2017
Completion date January 8, 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03993873 - Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET Phase 1/Phase 2
Recruiting NCT05494918 - First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors Phase 1
Completed NCT02281409 - Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01928459 - Phase 1b Trial of BGJ398/BYL719 in Solid Tumors Phase 1
Completed NCT01449370 - Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer Phase 1
Recruiting NCT06031441 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03059823 - A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors Phase 1
Terminated NCT03573544 - This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. Phase 1/Phase 2
Active, not recruiting NCT03893955 - A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00878423 - Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors Phase 1
Withdrawn NCT00149019 - Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies. Phase 2
Recruiting NCT03093116 - A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Phase 1/Phase 2
Terminated NCT03854227 - A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors Phase 1
Recruiting NCT04094610 - A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Phase 1/Phase 2
Active, not recruiting NCT01543763 - Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors Phase 1
Terminated NCT02228811 - A Study of DCC-2701 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05853367 - Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) Phase 1
Completed NCT02097810 - Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. Phase 1
Recruiting NCT05836324 - A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03910530 - A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors Phase 1